SEC Filings
Viatris Adds Non-Opioid Pain Business With Approximately $1.69 Billion Pacira Purchase
Viatris expects Pacira to contribute $90 million to $100 million in revenue for the remainder of 2026.
Viatris (VTRS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Viatris expects Pacira to contribute $90 million to $100 million in revenue for the remainder of 2026.
Earnings
A $453.2 million tax provision drove the third-quarter loss on flat sales, while the drugmaker lifted its adjusted EPS midpoint to $2.60.
Earnings
Scott Smith said the company is making "tremendous progress" toward its 2030 targets, while a halted Indian plant cost about $100 million in third-quarter revenue.
Deals
The all-cash tender offer adds Exparel and Zilretta, with a $62 million termination fee payable by Pacira in specified cases.